Brand Loyalty, Entry, and Price Competition in Pharmaceuticals after the 1984 Drug Act
1992; University of Chicago Press; Volume: 35; Issue: 2 Linguagem: Inglês
10.1086/467257
ISSN1537-5285
AutoresHenry G. Grabowski, John M. Vernon,
Tópico(s)Pharmaceutical industry and healthcare
ResumoPrevious articleNext article No AccessBrand Loyalty, Entry, and Price Competition in Pharmaceuticals after the 1984 Drug ActHenry G. Grabowski, and John M. VernonHenry G. Grabowski Search for more articles by this author , and John M. Vernon Search for more articles by this author PDFPDF PLUS Add to favoritesDownload CitationTrack CitationsPermissionsReprints Share onFacebookTwitterLinkedInRedditEmail SectionsMoreDetailsFiguresReferencesCited by The Journal of Law and Economics Volume 35, Number 2Oct., 1992 Sponsored by The University of Chicago Booth School of Business and The University of Chicago Law School Article DOIhttps://doi.org/10.1086/467257 Views: 136Total views on this site Citations: 330Citations are reported from Crossref Copyright 1992 The University of ChicagoPDF download Crossref reports the following articles citing this article:Robert Clark, Christopher Fabiilli, Laura Lasio Collusion in the US generic drug industry, International Journal of Industrial Organization 85 (Dec 2022): 102878.https://doi.org/10.1016/j.ijindorg.2022.102878Ziemowit Bednarek, Jacqueline M. Doremus, Sarah S. Stith, Haijun Yang U.S. cannabis laws projected to cost generic and brand pharmaceutical firms billions, PLOS ONE 17, no.88 (Aug 2022): e0272492.https://doi.org/10.1371/journal.pone.0272492Richard T. Thakor, Andrew W. Lo Competition and R&D Financing: Evidence From the Biopharmaceutical Industry, Journal of Financial and Quantitative Analysis 57, no.55 (Apr 2021): 1885–1928.https://doi.org/10.1017/S0022109021000284Cornelis W. Haasnoot, Albert de Vaal Heterogeneous firms and cluster externalities: how asymmetric effects at the firm level affect cluster productivity, Research Policy 51, no.66 (Jul 2022): 104529.https://doi.org/10.1016/j.respol.2022.104529Frank R. Lichtenberg The effects of dynamic and static competition on prescription drug prices in Denmark, 1997–2017, Journal of Evolutionary Economics 60 (Jun 2022).https://doi.org/10.1007/s00191-022-00777-4Kazuhiro Takauchi, Tomomichi Mizuno Endogenous transport price, R&D spillovers, and trade, The World Economy 45, no.55 (Oct 2021): 1477–1500.https://doi.org/10.1111/twec.13189Yixin (Iris) Wang, Jun Li, Ravi Anupindi Manufacturing and Regulatory Barriers to Generic Drug Competition: A Structural Model Approach, Management Science 37 (Apr 2022).https://doi.org/10.1287/mnsc.2022.4423Tianqin Shi, Nicholas C. Petruzzi, Dilip Chhajed The Effects of Patent Extension and Take-Back Regulation on Green Pharmacy, Manufacturing & Service Operations Management 24, no.22 (Mar 2022): 810–826.https://doi.org/10.1287/msom.2021.1009Maximiliane Unsorg Reference pricing systems on the pharmaceutical market, German Economic Review 0, no.00 (Jan 2022).https://doi.org/10.1515/ger-2020-0105Kyung-Bok Son, Eui-Kyung Lee Importance of a usual source of care in choosing low-priced generic drugs: a cross-sectional study, Family Practice 39 (Jan 2022).https://doi.org/10.1093/fampra/cmab172Arjun Watane, Meghana Kalavar, Joshua Reyes, Nicolas A Yannuzzi, Jayanth Sridhar The Effect of Market Competition on the Price of Topical Eye Drops, Seminars in Ophthalmology 37, no.11 (Mar 2021): 42–48.https://doi.org/10.1080/08820538.2021.1906918Frank R. Lichtenberg Are drug prices subject to creative destruction? Evidence from the US, 1997–2017, Health Economics 30, no.88 (May 2021): 1910–1932.https://doi.org/10.1002/hec.4283Alice M. Ellyson, Anirban Basu Do pharmaceutical prices rise anticipating branded competition?, Health Economics 30, no.55 (Mar 2021): 1070–1081.https://doi.org/10.1002/hec.4248Junghee Lee, Hyun Seok (Huck) Lee, Hyoduk Shin, Vish Krishnan Alleviating Drug Shortages: The Role of Mandated Reporting Induced Operational Transparency, Management Science 67, no.44 (Apr 2021): 2326–2339.https://doi.org/10.1287/mnsc.2020.3857Colleen Cunningham, Florian Ederer, and Song Ma Killer Acquisitions, Journal of Political Economy 129, no.33 (Feb 2021): 649–702.https://doi.org/10.1086/712506Yazed AlRuthia, Badr Aljohani, Wejdan R. Alsharif, Hala H. Alrasheed, Bushra M. Alghamdi, Shatha Asiri, Maryam Alarfaj, Ghadah S. Almuaythir, Saja Almazrou, Omar Almazroo, Ahmed Alaofi, Rawan Alenazi Prospects of Establishing a Saudi Version of the United States Food and Drug Administration Orange Book, Health Policy and Technology 10, no.11 (Mar 2021): 120–125.https://doi.org/10.1016/j.hlpt.2020.08.018Jihui Chen, Yi Wang The pricing effects of entry by Hainan airlines: Evidence from the U.S.-China international air travel market, Journal of Economics and Business 114 (Mar 2021): 105957.https://doi.org/10.1016/j.jeconbus.2020.105957Isabel Correia, Luís Armada, Paula Veiga Generics competition in the Portuguese pharmaceutical market, Journal of Generic Medicines: The Business Journal for the Generic Medicines Sector 17, no.11 (Sep 2020): 17–28.https://doi.org/10.1177/1741134320953875Nami Kim, Eonsoo Kim, Jongseon Lee Innovating by eliminating: Technological resource divestiture and firms’ innovation performance, Journal of Business Research 123 (Feb 2021): 176–187.https://doi.org/10.1016/j.jbusres.2020.09.054Yang Sun Index Fund Entry and Financial Product Market Competition, Management Science 67, no.11 (Jan 2021): 500–523.https://doi.org/10.1287/mnsc.2019.3444Jerónimo Cajellas, Debi Prasad Mohapatra Welfare Effects of Public Procurement of Medicines: Evidence from Ecuador, International Journal of Industrial Organization (Dec 2020): 102697.https://doi.org/10.1016/j.ijindorg.2020.102697David B. Ridley, Chung-Ying Lee Does Medicare Reimbursement Drive Up Drug Launch Prices?, The Review of Economics and Statistics 102, no.55 (Dec 2020): 980–993.https://doi.org/10.1162/rest_a_00849Pedro Bento Quantifying the Effects of Patent Protection on Innovation, Imitation, Growth, and Aggregate Productivity, The B.E. Journal of Macroeconomics 0, no.00 (Aug 2020).https://doi.org/10.1515/bejm-2019-0120Miguel González-Maestre, Lluís M. Granero Excessive vs. insufficient entry in spatial models: When product design and market size matter, Mathematical Social Sciences 106 (Jul 2020): 27–35.https://doi.org/10.1016/j.mathsocsci.2020.02.005Farasat A. S. Bokhari, Franco Mariuzzo, Arnold Polanski Entry limiting agreements: First‐mover advantage, authorized generics, and pay‐for‐delay deals, Journal of Economics & Management Strategy 29, no.33 (May 2020): 516–542.https://doi.org/10.1111/jems.12351Archita Sarmah, Domenico De Giovanni, Pietro De Giovanni Compulsory licenses in the pharmaceutical industry: Pricing and R&D strategies, European Journal of Operational Research 282, no.33 (May 2020): 1053–1069.https://doi.org/10.1016/j.ejor.2019.10.021Chung-Ying Lee Pricing strategy and moral hazard: Copay coupons in pharmaceuticals, International Journal of Industrial Organization 70 (May 2020): 102611.https://doi.org/10.1016/j.ijindorg.2020.102611Z. John Lu, William S. Comanor, Elliot Cherkas, Llad Phillips U.S. Pharmaceutical Markets: Expenditures, Health Insurance, New Products and Generic Prescribing from 1960 to 2016, International Journal of the Economics of Business 27, no.11 (Sep 2019): 1–26.https://doi.org/10.1080/13571516.2019.1651150Arzi Adbi, Ajay Bhaskarabhatla, Chirantan Chatterjee Stakeholder Orientation and Market Impact: Evidence from India, Journal of Business Ethics 161, no.22 (Jul 2018): 479–496.https://doi.org/10.1007/s10551-018-3919-xSabrina Terrizzi, Chad Meyerhoefer ESTIMATES OF THE PRICE ELASTICITY OF SWITCHING BETWEEN BRANDED AND GENERIC DRUGS, Contemporary Economic Policy 38, no.11 (Apr 2019): 94–108.https://doi.org/10.1111/coep.12430Marco J. W. Kotschedoff, Max J. Pachali Higher Minimum Quality Standards and Redistributive Effects on Consumer Welfare, Marketing Science 39, no.11 (Jan 2020): 253–280.https://doi.org/10.1287/mksc.2019.1172Jeffrey Fujimoto, Daniel M Tien, Sophie Snyder, Jeppe A Hertz, Stuart Schweitzer The effect of patent expiration on sales of branded competitor drugs in a therapeutic class, Journal of Generic Medicines: The Business Journal for the Generic Medicines Sector 15, no.44 (Jul 2019): 177–184.https://doi.org/10.1177/1741134319856408Jacquelyn W. Chou, Alison R. Silverstein, Dana P. Goldman Short-term budget affordability of hepatitis C treatments for state Medicaid programs, BMC Health Services Research 19, no.11 (Feb 2019).https://doi.org/10.1186/s12913-019-3956-xYoshimi Harada, Shintaro Sengoku The Key Success Factors of Biotech Start-Up Firms: Characteristics and Attributes of the Management Teams of High-Performing Biotech Start-Ups, (Aug 2019): 1–15.https://doi.org/10.23919/PICMET.2019.8893765Jennifer H. Mike A re‐evaluation of the framework for the protection of patents, women’s health in Nigeria and the issue of accessing pharmaceutical innovation in Africa: Designing strategies for medicines, The Journal of World Intellectual Property 22, no.3-43-4 (Jul 2019): 162–204.https://doi.org/10.1111/jwip.12123Micki Eisenman, Srikanth Paruchuri Inventor knowledge recombination behaviors in a pharmaceutical merger: The role of intra-firm networks, Long Range Planning 52, no.22 (Apr 2019): 189–201.https://doi.org/10.1016/j.lrp.2018.03.005Margaret E. Helmuth, Qian Liu, Marc N. Turenne, Jeong M. Park, Murewa Oguntimein, Sarah K. Dutcher, Rajesh Balkrishnan, Pratima Sharma, Jarcy Zee, Alan B. Leichtman, Abigail R. Smith Secular Trends in the Cost of Immunosuppressants after Solid Organ Transplantation in the United States, Clinical Journal of the American Society of Nephrology 14, no.33 (Feb 2019): 421–430.https://doi.org/10.2215/CJN.10590918Edward D. Perry, David A. Hennessy, GianCarlo Moschini Product concentration and usage: Behavioral effects in the glyphosate market, Journal of Economic Behavior & Organization 158 (Feb 2019): 543–559.https://doi.org/10.1016/j.jebo.2018.12.027Andrew T. Ching, Manuel Ignacio Hermosilla, Qiang Liu Structural Models of the Prescription Drug Market, SSRN Electronic Journal (Jan 2019).https://doi.org/10.2139/ssrn.3348196Pierre Dubois, Laura Lasio Identifying Industry Margins with Price Constraints: Structural Estimation on Pharmaceuticals, American Economic Review 108, no.1212 (Dec 2018): 3685–3724.https://doi.org/10.1257/aer.20140202Rajat Khanna, Isin Guler, Atul Nerkar Entangled decisions: Knowledge interdependencies and terminations of patented inventions in the pharmaceutical industry, Strategic Management Journal 39, no.99 (Aug 2018): 2439–2465.https://doi.org/10.1002/smj.2923Luke M. Olson, Brett W. Wendling Estimating the Causal Effect of Entry on Generic Drug Prices Using Hatch–Waxman Exclusivity, Review of Industrial Organization 53, no.11 (Apr 2018): 139–172.https://doi.org/10.1007/s11151-018-9627-yMiguel González-Maestre, Lluís M. Granero Competition with targeted product design: Price, variety, and welfare, International Journal of Industrial Organization 59 (Jul 2018): 406–428.https://doi.org/10.1016/j.ijindorg.2018.02.009Onesun Steve Yoo, Rakesh Sarin Consumer Choice and Market Outcomes Under Ambiguity in Product Quality, Marketing Science 37, no.33 (Jun 2018): 445–468.https://doi.org/10.1287/mksc.2017.1069Jörg Mahlich, Isao Kamae, Rosarin Sruamsiri Pharmaceutical pricing in Japan: market evidence for rheumatoid arthritis treatment, Expert Review of Pharmacoeconomics & Outcomes Research 18, no.33 (Nov 2017): 339–348.https://doi.org/10.1080/14737167.2018.1394187Susan J. Méndez Parallel trade of pharmaceuticals: The Danish market for statins, Health Economics 27, no.22 (Sep 2017): 333–356.https://doi.org/10.1002/hec.3551L. G. Thomas , ( 2018): 1311.https://doi.org/10.1057/978-1-137-00772-8_436Yunyun Wan , The Japanese Economic Review 69, no.33 ( 2018): 340.https://doi.org/10.1111/jere.12189Rajat Khanna, Isin Guler, Atul A. Nerkar Entangled Decisions: Knowledge Interdependencies and Terminations of Patented Inventions in the Pharmaceutical Industry, SSRN Electronic Journal (Jan 2018).https://doi.org/10.2139/ssrn.3158013Atanu Saha Strategic Deterrence: An Application to Biologic Pharmaceuticals, SSRN Electronic Journal (Jan 2018).https://doi.org/10.2139/ssrn.3204424Marco J.W. Kotschedoff, Max J. Pachali Higher Minimum Quality Standards and Redistributive Effects on Consumer Welfare, SSRN Electronic Journal (Jan 2018).https://doi.org/10.2139/ssrn.3214249Colleen Cunningham, Florian Ederer, Song Ma Killer Acquisitions, SSRN Electronic Journal (Jan 2018).https://doi.org/10.2139/ssrn.3241707John E. Thanassoulis The I.O. of Ethics and Cheating When Consumers Do Not Have Rational Expectations, SSRN Electronic Journal (Jan 2018).https://doi.org/10.2139/ssrn.3246870Juan Pablo Atal, José Ignacio Cuesta, Morten Sæthre Quality Regulation and Competition: Evidence from Pharmaceutical Markets, SSRN Electronic Journal (Jan 2018).https://doi.org/10.2139/ssrn.3263514Sharat Ganapati, Rebecca McKibbin Non-Tariff Barriers and Bargaining in Generic Pharmaceuticals, SSRN Electronic Journal (Jan 2018).https://doi.org/10.2139/ssrn.3313630Yixin (Iris) Wang, Jun Li, Ravi Anupindi Manufacturing and Regulatory Barriers to Generic Drug Competition: A Structural Model Approach, SSRN Electronic Journal (Jan 2018).https://doi.org/10.2139/ssrn.3145635Wei-Han Cheng, Étienne Gaudette, Dana P. Goldman PCSK9 Inhibitors Show Value for Patients and the US Health Care System, Value in Health 20, no.1010 (Dec 2017): 1270–1278.https://doi.org/10.1016/j.jval.2017.05.014Mats A. Bergman, David Granlund, Niklas Rudholm Squeezing the Last Drop Out of Your Suppliers: An Empirical Study of Market-Based Purchasing Policies for Generic Pharmaceuticals, Oxford Bulletin of Economics and Statistics 79, no.66 (Apr 2017): 969–996.https://doi.org/10.1111/obes.12180Oana Mihaescu, Niklas Rudholm DEFINING RELEVANT MARKETS FOR PHARMACEUTICALS, Bulletin of Economic Research 69, no.44 (Nov 2016): E126–E149.https://doi.org/10.1111/boer.12106Carl Rudolf Blankart, Tom Stargardt Preferred supplier contracts in post-patent prescription drug markets, Health Care Management Science 20, no.33 (Feb 2016): 419–432.https://doi.org/10.1007/s10729-016-9362-6Daigo Fukumoto, Ai Tsuyuki, Takeshi Suzuki Drugs Targeted for Price Cutting in Japan: The Case of Price Revisions Based on the Divergence of Official Versus Delivery Prices, Therapeutic Innovation & Regulatory Science 51, no.55 (Dec 2017): 597–603.https://doi.org/10.1177/2168479017705157Ali Bonakdar Tehrani, Norman V. Carroll The Medicaid Rebate: Changes in Oncology Drug Prices After the Affordable Care Act, Applied Health Economics and Health Policy 15, no.44 (Feb 2017): 513–520.https://doi.org/10.1007/s40258-017-0314-1Mikael Linden Price variability, generic substitution, market size and multimarket contacts in the Finnish beta blocker market, Economia e Politica Industriale 44, no.22 (Nov 2016): 161–174.https://doi.org/10.1007/s40812-016-0065-2Mingyue Zhao, Jing Wu Impacts of regulated competition on pricing in Chinese pharmaceutical market under urban employee basic medical insurance, Expert Review of Pharmacoeconomics & Outcomes Research 17, no.33 (Nov 2016): 311–320.https://doi.org/10.1080/14737167.2017.1251318Leemore Dafny, Christopher Ody, Matt Schmitt When Discounts Raise Costs: The Effect of Copay Coupons on Generic Utilization, American Economic Journal: Economic Policy 9, no.22 (May 2017): 91–123.https://doi.org/10.1257/pol.20150588Faris El-Dahiyat Pharmacoeconomic evidence and policies to promote use of generic medicines in Jordan, Pharmaceuticals Policy and Law 19, no.1-21-2 (Apr 2017): 71–86.https://doi.org/10.3233/PPL-170448Cristina Zerbini, Donata Tania Vergura, Beatrice Luceri Consumers' intention to buy generic drugs: Evidences from the Italian setting, MERCATI & COMPETITIVITÀ , no.11 (Mar 2017): 159–176.https://doi.org/10.3280/MC2017-001009Vardan Avagyan, Vardit Landsman, Stefan Stremersch Marketing Models for the Life Sciences Industry, (Jul 2017): 385–430.https://doi.org/10.1007/978-3-319-56941-3_13Mikyung Ryu, Juyoung Kim , BMC Health Services Research 17, no.11 ( 2017).https://doi.org/10.1186/s12913-017-2555-yTaehwan Kim Changing Market Conversion and Evolving Ways to Compete: Evidence from Retail Gasoline, SSRN Electronic Journal (Jan 2017).https://doi.org/10.2139/ssrn.3074941Patrick Leoni, Alvaro Sandroni Can patent duration hinder medical innovation, International Journal of Health Economics and Management 16, no.44 (Sep 2016): 397–406.https://doi.org/10.1007/s10754-016-9198-0Joan Costa-Font Is medicines parallel trade ‘regulatory arbitrage’?, International Journal of Health Economics and Management 16, no.44 (Sep 2016): 321–336.https://doi.org/10.1007/s10754-016-9199-zKurt R. Brekke, Chiara Canta, Odd Rune Straume Reference pricing with endogenous generic entry, Journal of Health Economics 50 (Dec 2016): 312–329.https://doi.org/10.1016/j.jhealeco.2016.04.003Mohsen Ali Murshid, Zurina Mohaidin, Goh Yen Nee The influence patient’s characteristics “requests and expectations” on physician prescribing behavior, International Journal of Pharmaceutical and Healthcare Marketing 10, no.44 (Nov 2016): 390–411.https://doi.org/10.1108/IJPHM-01-2016-0010Katharina Elisabeth Fischer, Tom Stargardt The diffusion of generics after patent expiry in Germany, The European Journal of Health Economics 17, no.88 (Nov 2015): 1027–1040.https://doi.org/10.1007/s10198-015-0744-3Lee Branstetter, Chirantan Chatterjee, Matthew J. Higgins Regulation and welfare: evidence from paragraph IV generic entry in the pharmaceutical industry, The RAND Journal of Economics 47, no.44 (Nov 2016): 857–890.https://doi.org/10.1111/1756-2171.12157Simon P. Anderson, Federico Ciliberto, Jura Liaukonyte, Régis Renault Push-me pull-you: comparative advertising in the OTC analgesics industry, The RAND Journal of Economics 47, no.44 (Nov 2016): 1029–1056.https://doi.org/10.1111/1756-2171.12162Chon Kit Chao, Hao Hu, Liming Zhang, Jihong Wu Managing the challenges of pharmaceutical patent expiry: a case study of Lipitor, Journal of Science and Technology Policy Management 7, no.33 (Oct 2016): 258–272.https://doi.org/10.1108/JSTPM-12-2015-0040William V. Padula, Richard A. Larson, Stacie B. Dusetzina, Jane F. Apperley, Rudiger Hehlmann, Michele Baccarani, Ekkehard Eigendorff, Joelle Guilhot, Francois Guilhot, Rudiger Hehlmann, Francois-Xavier Mahon, Giovanni Martinelli, Jiri Mayer, Martin C. Müller, Dietger Niederwieser, Susanne Saussele, Charles A. Schiffer, Richard T. Silver, Bengt Simonsson, Rena M. Conti Cost-effectiveness of Tyrosine Kinase Inhibitor Treatment Strategies for Chronic Myeloid Leukemia in Chronic Phase After Generic Entry of Imatinib in the United States, Journal of the National Cancer Institute 108, no.77 (Mar 2016): djw003.https://doi.org/10.1093/jnci/djw003Jianfei Guo, Christina Kelton Competition between Brand-Name and Generic Drugs, (May 2016): 181–193.https://doi.org/10.1201/b19633-13Rajat Khanna, Isin Guler, Atul Nerkar Fail Often, Fail Big, and Fail Fast? Learning from Small Failures and R&D Performance in the Pharmaceutical Industry, Academy of Management Journal 59, no.22 (Apr 2016): 436–459.https://doi.org/10.5465/amj.2013.1109Kerry M. Tan Incumbent Response to Entry by Low-Cost Carriers in the U.S. Airline Industry, Southern Economic Journal 82, no.33 (Nov 2015): 874–892.https://doi.org/10.1002/soej.12117Rena M. Conti, William V. Padula, Richard A. Larson Changing the Cost of Care for Chronic Myeloid Leukemia: The Availability of Generic Imatinib in the USA and the EU, (Aug 2016): 231–255.https://doi.org/10.1007/978-3-319-33198-0_15L. G. Thomas Potential Competition, (Jun 2016): 1–3.https://doi.org/10.1057/978-1-349-94848-2_436-1Susan J. Mendez Parallel Trade of Pharmaceuticals: The Danish Market for Statins, SSRN Electronic Journal (Jan 2016).https://doi.org/10.2139/ssrn.2740730Hye-Young Kwon, Hyungmin Kim, Brian Godman, Michael R Reich The impact of South Korea’s new drug-pricing policy on market competition among off-patent drugs, Expert Review of Pharmacoeconomics & Outcomes Research 15, no.66 (Sep 2015): 1007–1014.https://doi.org/10.1586/14737167.2015.1083425Karen Van Nuys, Ronald Brookmeyer, Jacquelyn W. Chou, David Dreyfus, Douglas Dieterich, Dana P. Goldman Broad Hepatitis C Treatment Scenarios Return Substantial Health Gains, But Capacity Is A Concern, Health Affairs 34, no.1010 (Oct 2015): 1666–1674.https://doi.org/10.1377/hlthaff.2014.1193Panagiotis Petrou, Michael A. Talias Price Determinants of the Tendering Process for Pharmaceuticals in the Cyprus Market, Value in Health Regional Issues 7 (Sep 2015): 67–73.https://doi.org/10.1016/j.vhri.2015.09.001Silvia Appelt Authorized Generic Entry prior to Patent Expiry: Reassessing Incentives for Independent Generic Entry, Review of Economics and Statistics 97, no.33 (Jul 2015): 654–666.https://doi.org/10.1162/REST_a_00488Mee-Hyun Cho, Ki-Bong Yoo, Hoo-Yeon Lee, Kwang-Sig Lee, Jeoung A Kwon, Kyu-Tae Han, Jae-Hyun Kim, Eun-Cheol Park The effect of new drug pricing systems and new reimbursement guidelines on pharmaceutical expenditures and prescribing behavior among hypertensive patients in Korea, Health Policy 119, no.55 (May 2015): 604–611.https://doi.org/10.1016/j.healthpol.2015.01.002Osamu Takizawa, Hisashi Urushihara, Shiro Tanaka, Koji Kawakami Price difference as a predictor of the selection between brand name and generic statins in Japan, Health Policy 119, no.55 (May 2015): 612–619.https://doi.org/10.1016/j.healthpol.2015.01.010Kathleen Iacocca, James Sawhill, Yao Zhao Why brand drugs priced higher than generic equivalents, International Journal of Pharmaceutical and Healthcare Marketing 9, no.11 (Apr 2015): 3–19.https://doi.org/10.1108/IJPHM-01-2014-0005Rena M. Conti, William V. Padula, Richard A. Larson Changing the cost of care for chronic myeloid leukemia: the availability of generic imatinib in the USA and the EU, Annals of Hematology 94, no.S2S2 (Mar 2015): 249–257.https://doi.org/10.1007/s00277-015-2319-xZoulikha Snoussi Tarif de référence et entrée des génériques : l’impact sur les prix des médicaments en Algérie, Revue d'économie industrielle , no.149149 (Mar 2015): 103–147.https://doi.org/10.4000/rei.6091Shanjun Li, Ramanan Laxminarayan Are Physicians' Prescribing Decisions Sensitive to Drug Prices? Evidence from a Free-antibiotics Program, Health Economics 24, no.22 (Oct 2013): 158–174.https://doi.org/10.1002/hec.3008Kurt Richard Brekke, Chiara Canta, Odd Rune Straume Reference Pricing with Endogenous Generic Entry, SSRN Electronic Journal (Jan 2015).https://doi.org/10.2139/ssrn.2594760Kurt Richard Brekke, Chiara Canta, Odd Rune Straume Does Reference Pricing Drive Out Generic Competition in Pharmaceutical Markets? Evidence from a Policy Reform., SSRN Electronic Journal (Jan 2015).https://doi.org/10.2139/ssrn.2617267Rajat Khanna, Isin Guler, Atul A. Nerkar Fail Often, Fail Big, and Fail Fast? Learning from Small Failures and R&D Performance in the Pharmaceutical Industry, SSRN Electronic Journal (Jan 2015).https://doi.org/10.2139/ssrn.2629419Joan Costa-Font, Alistair McGuire, Nebibe Varol Price regulation and relative delays in generic drug adoption, Journal of Health Economics 38 (Dec 2014): 1–9.https://doi.org/10.1016/j.jhealeco.2014.04.004Panos Kanavos Measuring performance in off-patent drug markets: A methodological framework and empirical evidence from twelve EU Member States, Health Policy 118, no.22 (Nov 2014): 229–241.https://doi.org/10.1016/j.healthpol.2014.08.005Brett Christophers On the Performativity of Pill Pricing: Theory and Reality in the Economics of Global Pharmaceuticalization, Antipode 46, no.44 (Feb 2014): 1054–1071.https://doi.org/10.1111/anti.12084Dr. Vivek Pande, Yu Yu, Yi Zhao The effect of Affordable Care Act on the competition in the post-patent ethical drug market, International Journal of Pharmaceutical and Healthcare Marketing 8, no.33 (Aug 2014): 314–347.https://doi.org/10.1108/IJPHM-12-2013-0066Fredric Blavin, Timothy Waidmann, Linda J. Blumberg, Jeremy Roth Trends in Prescription Drug Spending Leading Up to Health Reform, Medical Care Research and Review 71, no.44 (May 2014): 416–432.https://doi.org/10.1177/1077558714533820Ulrich Kaiser, Susan J. Mendez, Thomas Rønde, Hannes Ullrich Regulation of pharmaceutical prices: Evidence from a reference price reform in Denmark, Journal of Health Economics 36 (Jul 2014): 174–187.https://doi.org/10.1016/j.jhealeco.2014.04.003Joan Costa-Font, Caroline Rudisill, Stefanie Tan Brand loyalty, patients and limited generic medicines uptake, Health Policy 116, no.2-32-3 (Jun 2014): 224–233.https://doi.org/10.1016/j.healthpol.2014.01.015Jaume Puig-Junoy, Beatriz González López-Valcárcel Launch prices for new pharmaceuticals in the heavily regulated and subsidized Spanish market, 1995–2007, Health Policy 116, no.2-32-3 (Jun 2014): 170–181.https://doi.org/10.1016/j.healthpol.2014.02.015Sotiris Vandoros, Panos Kanavos Parallel Trade and Pharmaceutical Prices: A Game-theoretic Approach and Empirical Evidence from the European Union, The World Economy 37, no.66 (Mar 2013): 856–880.https://doi.org/10.1111/twec.12063Conceição Portela Reference pricing system in Portugal – Supply, demand, and the effect of reimbursement level, International Journal of Healthcare Management 7, no.22 (Jan 2014): 120–126.https://doi.org/10.1179/2047971913Y.0000000062Yu Yu, Sachin Gupta Pioneering advantage in generic drug competition, International Journal of Pharmaceutical and Healthcare Marketing 8, no.22 (May 2014): 126–150.https://doi.org/10.1108/IJPHM-11-2013-0063Sotiris Vandoros THERAPEUTIC SUBSTITUTION POST-PATENT EXPIRY: THE CASES OF ACE INHIBITORS AND PROTON PUMP INHIBITORS, Health Economics 23, no.55 (May 2013): 621–630.https://doi.org/10.1002/hec.2935Steven Tenn, Brett W Wendling Entry Threats and Pricing in the Generic Drug Industry, Review of Economics and Statistics 96, no.22 (May 2014): 214–228.https://doi.org/10.1162/REST_a_00382Christina M. L. Kelton, Lenisa V. Chang, Jeff J. Guo, Yan Yu, Edmund A. Berry, Boyang Bian, Pamela C. Heaton Firm- and Drug-Specific Patterns of Generic Drug Payments by US Medicaid Programs: 1991–2008, Applied Health Economics and Health Policy 12, no.22 (Feb 2014): 165–177.https://doi.org/10.1007/s40258-014-0083-zJing Wu, Judy Xu, Gordon Liu, Jiuhong Wu Pharmaceutical Pricing: An Empirical Study of Market Competition in Chinese Hospitals, PharmacoEconomics 32, no.33 (Nov 2013): 293–303.https://doi.org/10.1007/s40273-013-0099-5SOUMYANANDA DINDA, ARIJIT MUKHERJEE A Note on the Adverse Effect of Competition on Consumers, Journal of Public Economic Theory 16, no.11 (Jun 2013): 157–163.https://doi.org/10.1111/jpet.12044Elina Petrova Innovation in the Pharmaceutical Industry: The Process of Drug Discovery and Development, (Oct 2013): 19–81.https://doi.org/10.1007/978-1-4614-7801-0_2Vardit Landsman, Isabel Verniers, Stefan Stremersch The Successful Launch and Diffusion of New Therapies, (Oct 2013): 189–223.https://doi.org/10.1007/978-1-4614-7801-0_7Ya-Ming Liu, Chee-Ruey Hsieh Profit-Seeking Behavior of Medical Providers and Generic Competition in the Pharmaceutical Market: Evidence from Taiwan, The B.E. Journal of Economic Analysis & Policy 14, no.11 (Nov 2013): 241–275.https://doi.org/10.1515/bejeap-2013-0066Miguel GonzzlezzMaestre, Luis M. Granero Competition with Targeted Product Design: Price, Variety, and Welfare, SSRN Electronic Journal (Jan 2014).https://doi.org/10.2139/ssrn.2458856Patrick L. Leoni The Economics of an HIV/AIDS Vaccine, SSRN Electronic Journal (Jan 2014).https://doi.org/10.2139/ssrn.2515834Andrey Shastitko, Svetlana Golovanova, Alexander Kurdin, Vadim Novikov, Natalia Pavlova (Macroeconomic Effects of Competition Restrictions), SSRN Electronic Journal (Jan 2014).https://doi.org/10.2139/ssrn.2663920Charles Courtemanche, Art Carden Competing with Costco and Sam's Club: Warehouse Club Entry and Grocery Prices, Southern Economic Journal 80, no.33 (Jan 2014): 565–585.https://doi.org/10.4284/0038-4038-2012.135Makoto Kakinaka, Ryuta Ray Kato Regulated medical fee schedule of the Japanese health care system, International Journal of Health Care Finance and Economics 13, no.3-43-4 (Sep 2013): 301–317.https://doi.org/10.1007/s10754-013-9133-6Abby Alpert, Mark Duggan, Judith K. Hellerstein Perverse reverse price competition: Average wholesale prices and Medicaid pharmaceutical spending, Journal of Public Economics 108 (Dec 2013): 44–62.https://doi.org/10.1016/j.jpubeco.2013.08.010Mary E. Schramm, Michael Y. Hu Perspective: The Evolution of R&D Conduct in the Pharmaceutical Industry, Journal of Product Innovation Management 30 (Sep 2013): 203–213.https://doi.org/10.1111/jpim.12072Antonio Cabrales, Sergi Jiménez-Martín THE DETERMINANTS OF PRICING IN PHARMACEUTICALS: ARE US PRICES REALLY SO HIGH?, Health Economics 22, no.1111 (Jan 2013): 1377–1397.https://doi.org/10.1002/hec.2887Saradindu Bhaduri, Thomas Brenner Examining the determinants of drug launch delay in pre-TRIPS India, The European Journal of Health Economics 14, no.55 (Sep 2012): 761–773.https://doi.org/10.1007/s10198-012-0422-7Simon P. Anderson, Federico Ciliberto, Jura Liaukonyte Information content of advertising: Empirical evidence from the OTC analgesic industry, International Journal of Industrial Organization 31, no.55 (Sep 2013): 355–367.https://doi.org/10.1016/j.ijindorg.2013.06.002Peter Arcidiacono, Paul B. Ellickson, Peter Landry, David B. Ridley Pharmaceutical followers, International Journal of Industrial Organization 31, no.55 (Sep 2013): 538–553.https://doi.org/10.1016/j.ijindorg.2013.10.005Kathleen Iacocca, James Sawhill, Yao Zhao A multiple regression model to explain the cost of brand-drugs, Socio-Economic Planning Sciences 47, no.33 (Sep 2013): 238–246.https://doi.org/10.1016/j.seps.2012.11.001Rok Hren Impact of the Pharma Economic Act on Diffusion of Innovation and Reduction of Costs in the Hungarian Prescription Drug Market (2007–2010), Value in Health Regional Issues 2, no.22 (Sep 2013): 290–299.https://doi.org/10.1016/j.vhri.2013.06.013
Referência(s)